The oncogene BRAF (v-raf murine sarcoma viral oncogene homolog B1) is frequently mutated in melanoma (40–50% of cases) and has resulted in the development of BRAF-targeting kinase inhibitors, like vemurafenib (PLX4032) and dabrafenib [2]–[4]. This evidence concerns the gene BRAF and melanoma.